Shingles

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.

The FDA approves a prefilled syringe for the zoster vaccine recombinant, enhancing shingles vaccination convenience and effectiveness for adults 50 years and older.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

The risk of developing HZ in this population is 10 to 30 times higher than in the general population.

Results support a 2020 meta-analysis showing that older adults with chronic pain are nearly twice as likely to develop frailty compared to those without chronic pain.

Antiviral treatments can accelerate healing and reduce complications.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

The findings suggest that VZV is a common cause of CNS infections, even when there is no visible rash.

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

Although shingles is more common in adults, children who have had chickenpox or the chickenpox vaccine can develop shingles.

An increase of shingles vaccination was reported among individuals with asthma.